MRCP Part 1: Churg-Strauss, Wegener & Goodpasture

TL;DR

Eponyms: Churg-Strauss, Wegener, Goodpasture remain highly testable conditions in MRCP Part 1, particularly when questions compare vasculitis, pulmonary-renal syndromes and autoantibody profiles. Candidates should recognise the modern disease names, understand the associated antibodies, identify distinguishing clinical features and avoid common diagnostic traps. This guide summarises the highest-yield facts, provides a comparison table, an exam-style case and practical revision advice.

Why this matters

These disorders appear repeatedly because they test several core competencies:

• Autoantibody interpretation

• Pulmonary-renal syndromes

• Small-vessel vasculitis

• Renal pathology

• Respiratory manifestations

• Immunology

• Appropriate treatment

Many MRCP questions present similar symptoms—haemoptysis, renal impairment or constitutional illness—and require identification of the underlying disease.

Core sections

1. Churg-Strauss Syndrome (EGPA)

Definition

EGPA is an ANCA-associated necrotising small-vessel vasculitis characterised by:

• asthma

• eosinophilia

• eosinophilic tissue infiltration

• granulomatous inflammation

Unlike GPA, asthma is the defining clinical clue.

High-yield clinical features

• Adult-onset asthma

• Allergic rhinitis

• Nasal polyps

• Peripheral eosinophilia

• Mononeuritis multiplex

• Purpura

• Pulmonary infiltrates

• Cardiac involvement

• Peripheral neuropathy

Laboratory findings

• Marked eosinophilia

• Raised IgE

• Elevated inflammatory markers

• MPO-ANCA (p-ANCA) positive in approximately 40–60%

Major complications

• Cardiomyopathy

• Myocarditis

• Peripheral neuropathy

• Renal involvement (usually milder than GPA)

2. Wegener's Granulomatosis (GPA)

Definition

GPA is a necrotising granulomatous vasculitis affecting:

• upper respiratory tract

• lungs

• kidneys

This classic triad is extremely important for MRCP.

Typical presentation

Upper airway

• chronic sinusitis

• epistaxis

• nasal crusting

• saddle-nose deformity

Respiratory

• cough

• haemoptysis

• pulmonary nodules

• cavitating lesions

Renal

• rapidly progressive glomerulonephritis

Other features

• episcleritis

• arthritis

• purpura

• neuropathy

Laboratory findings

• c-ANCA

• PR3 antibodies

• active urinary sediment

• elevated inflammatory markers

3. Goodpasture Syndrome

Definition

Goodpasture syndrome is caused by antibodies directed against the alpha-3 chain of type IV collagen within the glomerular and alveolar basement membranes.

It is not an ANCA-associated vasculitis, although overlap can occasionally occur.

Typical presentation

Classic pulmonary-renal syndrome:

• haemoptysis

• rapidly progressive renal failure

• haematuria

• proteinuria

Diagnosis

• Anti-GBM antibodies

• Kidney biopsy:

  • crescentic glomerulonephritis

  • linear IgG deposition on immunofluorescence

The phrase linear IgG is one of the highest-yield pathology facts for MRCP.

4. High-Yield Comparison Table

Feature	EGPA (Churg-Strauss)	GPA (Wegener)	Goodpasture
Asthma	Yes (hallmark)	Rare	No
Eosinophilia	Marked	No	No
ANCA	MPO (p-ANCA)	PR3 (c-ANCA)	Usually negative
Pulmonary infiltrates	Yes	Yes	Alveolar haemorrhage
Cavitating nodules	Rare	Common	No
Sinus disease	Common	Very common	Rare
Renal disease	Mild to moderate	Severe	Severe
Granulomas	Yes	Yes	No
Anti-GBM antibody	No	No	Yes
Immunofluorescence	Pauci-immune	Pauci-immune	Linear IgG

5. Five Most Tested Subtopics

1. ANCA patterns

Remember:

• GPA → c-ANCA → PR3

• EGPA → p-ANCA → MPO

• Goodpasture → Anti-GBM antibody

2. Pulmonary-renal syndromes

Always consider:

• GPA

• Goodpasture syndrome

• Microscopic polyangiitis

The antibody profile often differentiates them.

3. Histology

MRCP commonly asks biopsy findings.

GPA

• Necrotising granulomas

EGPA

• Eosinophilic granulomas

Goodpasture

• Crescentic GN with linear IgG

4. Respiratory clues

Asthma strongly suggests EGPA.

Chronic sinusitis with cavitating lung lesions strongly suggests GPA.

Massive alveolar haemorrhage with renal failure strongly suggests Goodpasture syndrome.

5. Treatment principles

Although treatment protocols evolve, examination candidates should recognise:

EGPA

• Corticosteroids

• Immunosuppressants

• Biologics in selected patients

GPA

• Corticosteroids

• Rituximab

• Cyclophosphamide

Goodpasture

• Plasma exchange

• Corticosteroids

• Cyclophosphamide

High-Yield Revision Points

1. EGPA almost always develops in patients with asthma.

2. GPA commonly causes chronic sinus disease.

3. Goodpasture syndrome is mediated by anti-GBM antibodies.

4. GPA is classically associated with PR3 (c-ANCA).

5. EGPA is associated with eosinophilia.

6. Linear IgG staining strongly suggests Goodpasture disease.

7. Pauci-immune GN occurs in GPA and EGPA.

8. Pulmonary haemorrhage plus nephritis should immediately prompt consideration of Goodpasture syndrome.

9. Saddle-nose deformity is highly suggestive of GPA.

10. Cardiac disease is a major cause of mortality in EGPA.

Practical examples / mini-cases

Mini Case

A 48-year-old man presents with haemoptysis, haematuria and rapidly deteriorating renal function. Chest radiography demonstrates diffuse alveolar infiltrates. Anti-GBM antibodies are strongly positive.

Which diagnosis is most likely?

A. EGPA

B. GPA

C. Goodpasture syndrome

D. Microscopic polyangiitis

E. Polyarteritis nodosa

Answer

C. Goodpasture syndrome

Explanation

The combination of pulmonary haemorrhage, rapidly progressive glomerulonephritis and positive anti-GBM antibodies is classic for Goodpasture syndrome. GPA may also produce pulmonary-renal disease but is usually associated with PR3-ANCA and granulomatous upper airway disease.

Practical study-tip checklist

✔ Learn both historical and modern disease names.

✔ Memorise the antibody associations.

✔ Compare pulmonary findings between diseases.

✔ Recognise pathology descriptions.

✔ Revise pulmonary-renal syndromes together rather than separately.

✔ Know which disease presents with asthma.

✔ Distinguish pauci-immune from linear immunofluorescence.

✔ Practise image-based pathology and chest imaging questions.

For additional practice, work through the Free MRCP MCQs:/qbank/

Then consolidate with timed practice using:/mock-tests/

Video explanations are available in the MRCP video lectures:/lectures/

Common pitfalls (5 bullets)

• Confusing GPA with Goodpasture because both can cause haemoptysis and renal failure.

• Forgetting that asthma is the hallmark feature of EGPA.

• Mixing up c-ANCA (PR3) and p-ANCA (MPO).

• Assuming Goodpasture syndrome is an ANCA-associated vasculitis.

• Forgetting that linear IgG deposition is unique to anti-GBM disease.

FAQs

Is Wegener's granulomatosis still used in MRCP?

Modern practice uses Granulomatosis with Polyangiitis (GPA), but examination questions and older resources may still reference Wegener's granulomatosis. Candidates should recognise both names.

Which antibody is associated with Goodpasture syndrome?

Goodpasture syndrome is associated with anti-glomerular basement membrane (anti-GBM) antibodies, directed against type IV collagen.

What is the hallmark feature of EGPA?

Asthma combined with marked eosinophilia is the classic clinical combination that distinguishes EGPA from other ANCA-associated vasculitides.

How can GPA be distinguished from EGPA?

GPA typically presents with chronic sinus disease, cavitating lung lesions and PR3 (c-ANCA), whereas EGPA presents with asthma, eosinophilia and MPO (p-ANCA).

Which pathology finding is most characteristic of Goodpasture syndrome?

Linear IgG deposition along the glomerular basement membrane on immunofluorescence is the classic pathological finding.

Ready to start?

Mastering these classic eponyms improves performance across rheumatology, nephrology, respiratory medicine and immunology questions in MRCP Part 1. After reviewing this guide, reinforce your understanding with question-based learning using the Free MRCP QBank, then assess your progress with full-length mock examinations. For further reading, see our related articles on ANCA-associated vasculitis revision and Pulmonary-renal syndromes, which build directly on the concepts discussed here.

Sources

• MRCP(UK). MRCP Part 1 Examination Information. https://www.mrcpuk.org/

• KDIGO Clinical Practice Guideline for Glomerular Diseases.

• EULAR Recommendations for the Management of ANCA-Associated Vasculitis.

• British Society for Rheumatology Guidelines.

• Davidson's Principles and Practice of Medicine, latest edition.

• Oxford Handbook of Clinical Medicine, latest edition.